

ongoing trials - trial from www.clinicaltrials.gov

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis - - RECRUITING

Code: NCT06429176 **Year:** 2024 **Date:** 2024

Author:

Participants

adult patients with cystic fibrosis (CF). -

Interventions

multiple doses of the study drug, SPL84drug SPL84 or a placebo by inhalation every week for 9 weeks months

Outcome measures

Safety and effectiveness. Patients will Visit the clinic approximately 14 times over 17.5 weeks for checkups and tests". Number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs), Incidence, nature, and severity of AEs and SAEs, Day 1 through Day 87

<https://clinicaltrials.gov/study/NCT06429176>

Keywords

SPL84; Respiratory System Agents; pharmacological_intervention;